-- Gilead Sciences (GILD) said Tuesday it completed the acquisition of Arcellx in a deal worth $7.8 billion, which paid target investors $115 in cash along with a $5 contingent value right for each share owned.
The contingent payout requires an experimental multiple myeloma therapy to generate at least $6 billion in worldwide net sales through 2029, the company said.
The acquisition grants full ownership of the treatment to eliminate future royalty and milestone obligations, Gilead Sciences said.
The resulting accounting impact is projected to lower 2026 diluted earnings by approximately $5.57 to $5.67 per share, the company added.
Price: $128.82, Change: $+1.07, Percent Change: +0.84%